Breaking News, Collaborations & Alliances

Exogenus Therapeutics Chooses Lonza to Manufacture Exo-101

Lonza will develop a GMP-compliant process from its Siena (IT) site.

By: Rachel Klemovitch

Assistant Editor

Exogenus Therapeutics, a Portuguese biotech company, and Lonza, a global development and manufacturing company, have entered a partnership to develop Exo-101, Exogenus’ exosome-based lead candidate. Under the agreement, Lonza will leverage its expertise in exosome development and analytical services from its Siena (IT) site to define a GMP-compliant process for Exo-101 production. Production will be based on the foundational work from Exogenus Therapeutics. This feasibility effort aims to def...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters